All In Biotech

Drug Trial Radar · NCT07570173

A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 340 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

340

Planned (sponsor's estimate)

Start

May 18, 2026

Primary completion

Oct 18, 2033

Study completion Oct 18, 2033

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
May 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat people with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) that is CD19 positive using a medicine called MK-1045. MK-1045 is an immunotherapy, which is a treatment that helps the immune system fight cancer. This trial will compare MK-1045 to a standard immunotherapy called blinatumomab. The goals of this trial are to learn if more people who receive MK-1045 have no cancer cells in their bone marrow compared to people who receive blinatumomab and if people who receive MK-1045 live longer compared to people who receive blinatumomab.

Conditions

  • B-cell Acute Lymphoblastic Leukemia

Interventions

  • MK-1045Biological

    Intravenous administration

  • BlinatumomabBiological

    Intravenous administration

  • AcetaminophenDrug

    Oral administration as a premedication

  • DiphenhydramineDrug

    Intravenous administration as a premedication

  • DexamethasoneDrug

    Intravenous administration as a premedication

  • TocilizumabDrug

    Intravenous administration as a rescue medication

  • SiltuximabDrug

    Intravenous administration as a rescue medication

  • AvtozmaDrug

    Intravenous administration as a rescue medication

  • TyenneDrug

    Intravenous administration as a rescue medication

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Complete Remission (CR) in Study Part 1 and Part 2Time frame: 3 treatment cycles (up to approximately 126 days; each cycle is up to 42 days; cycle lengths vary between cycle and arm)
  2. Percentage of Participants Who Experience an Adverse Event (AE) in Study Part 1Time frame: 3 treatment cycles (up to approximately 126 days; each cycle is up to 42 days; cycle lengths vary between cycle and arm)
  3. Percentage of Participants Who Discontinue Study Intervention Due to an AE in Study Part 1Time frame: 3 treatment cycles (up to approximately 126 days; each cycle is up to 42 days; cycle lengths vary between cycle and arm)
  4. Overall Survival (OS) in Study Part 2Time frame: Up to approximately 7 years

Locations

30 sites in 10 countries. Site status is shown where the registry gives one.

  • Princess Margaret Cancer Center ( Site 0102)

    Toronto, Ontario, Canada · Recruiting

  • Rigshospitalet ( Site 0802)

    Copenhagen, Capital Region, Denmark · Recruiting

  • Aarhus Universitetshospital. Hæmatologisk afdeling ( Site 0804)

    Aarhus Nord, Central Jutland, Denmark · Recruiting

  • Odense Universitetshospital ( Site 0801)

    Odense C, Region Syddanmark, Denmark · Recruiting

  • CHU Bordeaux Haut-Leveque ( Site 4103)

    Pessac, Gironde, France · Recruiting

  • Hopital Saint-Louis ( Site 4100)

    Paris, Île-de-France Region, France · Recruiting

  • University Hospital of Ioannina ( Site 5103)

    Ioannina, Greece · Recruiting

  • Evangelismos General Hospital of Athens ( Site 5100)

    Athens, Attica, Greece · Recruiting

  • General Hospital of Athens "Laiko" ( Site 5101)

    Athens, Attica, Greece · Recruiting

  • General Hospital of Athens "Laiko" ( Site 5104)

    Athens, Attica, Greece · Recruiting

  • University General Hospital ''Attikon'' - General Hospital of West Attica "H AGIA VARVARA" ( Site 5102)

    Chaïdári, Attica, Greece · Recruiting

  • Rambam Health Care Campus ( Site 0903)

    Haifa, Israel · Recruiting

  • Haddasah Medical Center ( Site 0900)

    Jerusalem, Israel · Recruiting

  • Sheba Medical Center ( Site 0902)

    Ramat Gan, Israel · Recruiting

  • Sourasky Medical Center. ( Site 0904)

    Tel Aviv, Israel · Recruiting

  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII ( Site 1002)

    Bergamo, Lombardy, Italy · Recruiting

  • Policlinico Universitario Agostino Gemelli ( Site 1003)

    Rome, Roma, Italy · Recruiting

  • Tokyo Metropolitan Komagome Hospital ( Site 2106)

    Bunkyo, Tokyo, Japan · Recruiting

  • Toranomon Hospital ( Site 2101)

    Minato, Tokyo, Japan · Recruiting

  • Radboud UMC ( Site 2003)

    Geert Grooteplein-Zuid 8, Gelderland, Netherlands · Recruiting

  • Amsterdam UMC ( Site 2001)

    Amsterdam, North Holland, Netherlands · Recruiting

  • Erasmus Medisch Centrum ( Site 2000)

    Rotterdam, South Holland, Netherlands · Recruiting

  • Hospital General Universitario Gregorio Marañón ( Site 3003)

    Madrid, Spain · Recruiting

  • HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 3009)

    Madrid, Spain · Recruiting

  • Hospital Universitario de Salamanca ( Site 3002)

    Salamanca, Spain · Recruiting

  • Institut Català d'Oncologia (ICO) - Badalona ( Site 3001)

    Badalona, Barcelona, Spain · Recruiting

  • Clinica Universidad de Navarra ( Site 3006)

    Pamplona, Navarre, Spain · Recruiting

  • Hospital Universitario Central de Asturias ( Site 3008)

    Oviedo, Principality of Asturias, Spain · Recruiting

  • HOSPITAL CLINICO DE VALENCIA ( Site 3005)

    Valencia, Valenciana, Comunitat, Spain · Recruiting

  • Karolinska Universitetssjukhuset ( Site 4002)

    Stockholm, Stockholm County, Sweden · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.